Navigation Links
Aeterna Zentaris Presents Positive Phase 2 Efficacy and Safety Data for AEZS-108 in Advanced Endometrial Cancer at ENA Meeting in Berlin, Germany
Date:11/18/2010

ood tolerability of AEZS-108 was also reflected by a low rate of severe possibly drug-related non-hematological adverse events and which included single cases (2.4%) each of nausea, diarrhea, fatigue, general health deterioration (Grade 4), creatinine elevation, and blood potassium decrease. No cardiac toxicity was reported. Conclusion

  • AEZS-108 at a dosage of 267 mg/m2 every 3 weeks was active and well tolerated in patients with endometrial cancer.
  • Hematological toxicity was rapidly reversible, and non-hematological toxicities were usually not severe, causing few deviations from scheduled treatment.
  • The objective response rate of 31% compares well with those of single agent platinum or taxane treatment; responders included patients pre-treated with platinum/taxane combination.
  • In addition, the rate of stable disease was 44%, resulting in a Clinical Benefit Rate of 74%.
  • The overall survival after single agent AEZS-108 is similar to that reported for modern triple combination chemotherapy, but was achieved with lower toxicity. 
  • The abstract is available at: cr="true" href="http://www.aezsinc.com/temp/poster378.html">http://www.aezsinc.com/temp/poster378.html About Endometrial Cancer This year, the American Cancer Society estimates that more than 43,000 cases of endometrial cancer - tumors in the lining of the uterus and the glands of the endometrium - will be diagnosed in the United States. Symptoms can include unexplained vaginal bleeding, painful urination, painful intercourse and soreness in the pelvic area. There is no routine test to identify endometrial cancer. Treatment options include surgery, radiation therapy, hormone therapy and chemotherapy; however, there are new treatments in development that work by targeting and destroying cancerous cells. About AEZS-108 AEZS-108 represents a new targeting concept in
    '/>"/>

    SOURCE AETERNA ZENTARIS INC.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11

    Related biology technology :

    1. Aeterna Zentaris Presents Encouraging Preclinical Data on Two Novel Orally Active Anti-Cancer Compounds at Major Conference in Germany
    2. Aeterna Zentaris Reports Third Quarter 2010 Financial and Operating Results
    3. Aeterna Zentaris Announces Orphan Drug AEZS-130 (Macimorelin, Solorel(TM)) Interim Phase 3 Data Analysis Shows Potential for 2011 Filing as Oral Diagnostic Test for Adult Growth Hormone Deficiency (AGHD)
    4. Aeterna Zentaris Announces NIH Grant for a Phase 1/2 Study in Advanced Prostate Cancer with AEZS-108
    5. Aeterna Zentaris to Announce Second Quarter 2010 Financial and Operating Results on August 12, 2010
    6. Aeterna Zentaris to Present at Upcoming Canaccord Genuity 30th Annual Growth Conference 2010 on August 12
    7. Aeterna Zentaris Announces Perifosine Has Received Orphan-Drug Designation for the Treatment of Neuroblastoma
    8. Aeterna Zentaris: Perifosine Data Selected for Oral Presentation at Upcoming 12th World Congress on Gastrointestinal Cancer
    9. Aeterna Zentaris Announces Collaboration with Almac to Develop Therapy and Companion Diagnostic in Cancer
    10. Aeterna Zentaris Receives US$12 Million on Closing of Registered Direct Offering
    11. Aeterna Zentaris to Raise US$12 Million in Registered Direct Offering
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/3/2015)... , Aug. 3, 2015  Merck KGaA, Darmstadt, ... and top-quality high-tech products in the healthcare, life science ... US-based company Nano-C, their development and launch of promising ... photovoltaics (OPV). Merck KGaA, Darmstadt, Germany ... growing OPV sector. Novel derivatives: highly stable, ...
    (Date:8/3/2015)... -- E-QURE Corp. (OTCQB: EQUR), a Delaware ... Therapy device ("BST Device"), a new and novel electrotherapy ... wounds, today announced that the Company has signed its ... in medical devices, for the marketing and distribution of ... years old, sales, marketing and distribution company in ...
    (Date:8/3/2015)... 3, 2015 /PRNewswire/ - RepliCel Life Sciences Inc. (TSX.V: RP) ... the development of autologous cell therapies, announced today that RepliCel,s ... InvestMNT conference held in Minneapolis, Minnesota ... Hall,s presentation will highlight RepliCel,s 18-month milestones including CE Mark ... Europe , clinical data from both RCT-01 (tendon) and ...
    (Date:7/31/2015)... ... July 31, 2015 , ... ... market analysis and premium industry insights on the global resorcinol industry. The report ... collective study of vivid market scenarios and analysis of primary and secondary inputs ...
    Breaking Biology Technology:Merck KGaA, Darmstadt, Germany, and Nano-C Present Enhanced Materials for Organic Photovoltaics 2Merck KGaA, Darmstadt, Germany, and Nano-C Present Enhanced Materials for Organic Photovoltaics 3Merck KGaA, Darmstadt, Germany, and Nano-C Present Enhanced Materials for Organic Photovoltaics 4E-QURE Corp Signs Second Distribution Agreement in Israel 2E-QURE Corp Signs Second Distribution Agreement in Israel 3RepliCel Presenting at InvestMNT Investor Conference in Minneapolis 2Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 2Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 3Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 4
    ... known as eosinophils have a central role in causing ... Hospital, Boston, has developed approaches to noninvasively visualize in ... mice with a disease that mimics asthma (experimental allergic ... developed to help assess the efficacy of treatments (both ...
    ... Ticket Software LLC as State,s,Fastest Growing Technology Company, ... Technology,Council and the accounting firm UHY LLP feted ... night at the Chevrolet Theater in,Wallingford. The list ... and included such well known brands as Priceline.com ...
    ... (Nasdaq: MEMY ) today announced that Michael Smith, ... a company update at,the Rodman & Renshaw Annual Global ... EST at the New York Palace Hotel, in New,York ... of the presentation by,visiting the "Investors" section of Memory ...
    Cached Biology Technology:Connecticut Technology Council Honors UHY LLP Tech Top 40 Winners 2Connecticut Technology Council Honors UHY LLP Tech Top 40 Winners 3Connecticut Technology Council Honors UHY LLP Tech Top 40 Winners 4
    (Date:6/30/2015)... Genisphere announced Tom Bliss ... further develop Genisphere,s therapeutics capabilities and portfolio. Mr. Bliss ... much of the last 25 years in leadership positions ... Johnson & Johnson. Tom started his career in Investment ... Finance. He graduated from Dartmouth College with a BA ...
    (Date:6/26/2015)... Utah , June 26, 2015 ATL Technology, ... and devices with specialties in single use solutions, headquartered in ... of MedConx, Inc. (a California corporation ... and San Jose, Costa Rica ). ... Costa Rica with ATL Technology,s existing facility ...
    (Date:6/25/2015)... SALT LAKE CITY , June 25, 2015 /PRNewswire/ ... the first steps toward a healthier, happier life. That,s ... app is designed to do. The cutting-edge, portable health ... and offers real-life solutions to help improve your lifestyle ... Sellers Association awards dinner and gala Wednesday night, USANA,s ...
    Breaking Biology News(10 mins):Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3ATL Technology Announces Acquisition of MedConx, Inc. and Expanded Global Footprint 2@USANAinc's Personalized Nutrition Program Wins Industry Innovation Award 2
    ... at St. Jude Children,s Research Hospital have identified inherited variations ... acute lymphoblastic leukemia (ALL), including a gene that may help ... complete search of the human genetic blueprint or genome to ... childhood cancer. Published in the August 16 advance online issue ...
    ... at the Keck School of Medicine of the University ... mechanism that may govern an individual,s risk of developing ... Public Library of Science (PLoS) Genetics journal, ... no genes are present (gene ,deserts,) at a chromosomal ...
    ... at WPTRC is as diverse as the agencies that fund ... and studying the ecosystems of the island and the region. ... urging his,faculty to find new sources of external funds, and ... funding agencies that are now supporting the WPTRC and its ...
    Cached Biology News:Inherited risk factors increase odds of developing childhood acute lymphoblastic leukemia 2Inherited risk factors increase odds of developing childhood acute lymphoblastic leukemia 3UOG scientists successfully compete for research grants 2
    Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
    Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
    Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
    Request Info...
    Biology Products: